Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is actively engaged in the development of recombinant proteins and cell immunotherapy, with a focus on various disease targets and biomarkers, benefiting from the depreciation of the RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise [2][3][4]. Group 1: Company Overview - The company was established on July 22, 2010, and went public on October 18, 2021, primarily providing recombinant proteins and key biological reagent products and technical services [8]. - The main revenue composition includes 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [8]. Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 387 million yuan, representing a year-on-year growth of 29.38%, and a net profit attributable to shareholders of 83.8 million yuan, up 47.81% year-on-year [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan in the last three years [10]. Group 3: Market Position and Recognition - The company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong innovation capabilities and high market share in niche markets [3]. - As of the 2024 annual report, overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. Group 4: Recent Developments - The company has developed various high-quality recombinant proteins and is expanding its product offerings in the CAR-T cell therapy field, including specific antibodies and various reagent kits [2]. - The company has initiated product development related to monkeypox virus in response to its spread, launching multiple recombinant proteins, antibodies, and reagent kits to support vaccine and therapeutic drug development [2].

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is experiencing a decline in stock price and trading volume, while also benefiting from its innovative biotechnological developments and international revenue growth due to currency depreciation [1][4]. Group 1: Company Performance - On September 4, the company's stock dropped by 7.79%, with a trading volume of 350 million yuan and a market capitalization of 10.138 billion yuan [1]. - For the first half of 2025, the company achieved a revenue of 387 million yuan, representing a year-on-year growth of 29.38%, and a net profit of 83.804 million yuan, up 47.81% year-on-year [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan in the last three years [10]. Group 2: Product Development and Innovations - The company has developed a range of high-quality recombinant proteins targeting various diseases, which supports the research and production of biopharmaceuticals [2]. - It has launched a specific antibody targeting the CD19 antigen for CAR-T cell therapy, enhancing detection methods and expanding its product offerings in cell and gene therapy [2]. - The company is actively developing products related to monkeypox virus prevention and treatment, having already launched several recombinant proteins, antibodies, and test kits [2]. Group 3: Market Position and Recognition - The company has been recognized as a "specialized and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [3]. - As of the 2024 annual report, overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the yuan [4]. - The company operates in the pharmaceutical and biotechnology sector, focusing on recombinant proteins, antibodies, and technical services, with a revenue composition of 82.27% from recombinant proteins [8].

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., has shown significant growth in its stock performance and business operations, particularly in the fields of recombinant proteins and cell immunotherapy, benefiting from various market trends and developments [1][2][4]. Company Overview - Beijing Baipusais Biotechnology Co., Ltd. was established on July 22, 2010, and went public on October 18, 2021. The company specializes in providing key biological reagent products and technical services, with its main business revenue composition being 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [8]. Financial Performance - For the first half of 2025, the company achieved a revenue of 387 million yuan, representing a year-on-year growth of 29.38%. The net profit attributable to the parent company was 83.8 million yuan, reflecting a year-on-year increase of 47.81% [9]. - As of June 30, 2025, the company had a total market capitalization of 10.994 billion yuan, with a trading volume of 352 million yuan and a turnover rate of 4.46% [1][9]. Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is the highest honor for small and medium-sized enterprises in China, indicating its strong market position and innovation capabilities [3]. - The company benefits from a significant overseas revenue share, accounting for 66.46% of its total revenue, which is positively impacted by the depreciation of the Chinese yuan [4]. Product Development and Innovation - The company has developed a range of high-quality recombinant proteins targeting various disease markers and has expanded its product offerings in the CAR-T cell therapy field, including specific antibodies and various assay kits [2]. - The company is actively developing products related to monkeypox virus prevention and treatment, having launched multiple recombinant proteins, antibodies, and assay kits [2].

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is experiencing growth in its business driven by its innovative biotechnological products and services, particularly in recombinant proteins and CAR-T cell therapies, while also benefiting from the depreciation of the RMB [2][4]. Group 1: Business Performance - The company reported a revenue of 387 million yuan for the first half of 2025, representing a year-on-year growth of 29.38% [9]. - The net profit attributable to the parent company for the same period was 83.8 million yuan, showing a year-on-year increase of 47.81% [9]. - The company's overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Product Development - The company has developed a range of high-quality recombinant proteins targeting various diseases, which supports the research and production of biopharmaceuticals [2]. - It has launched a specific antibody targeting the CD19 antigen in CAR-T cell therapy, enhancing detection methods and expanding its product offerings in cell and gene therapy [2]. - The company is actively developing products related to monkeypox virus, including recombinant proteins and antibodies, to support vaccine and therapeutic drug development [2]. Group 3: Industry Recognition - The company has been recognized as a "specialized and innovative" small giant enterprise, which is a prestigious title in China for companies excelling in niche markets and possessing strong innovation capabilities [3]. - It is positioned within the pharmaceutical and biotechnology industry, specifically in the bioproducts sector, and is involved in various concepts such as biomedicine and monkeypox [9]. Group 4: Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased by 10.85% to 11,700, with an average of 7,711 shares held per shareholder, a decrease of 9.79% [9]. - The stock price has shown some upward movement, with a recent increase of 2.08% and a total market capitalization of 10.042 billion yuan [1].

Financial Performance - In the first half of 2025, the company achieved a revenue of 38,736.49 million CNY, representing a year-on-year growth of 29.38% [1] - The net profit attributable to shareholders was 8,380.40 million CNY, with a year-on-year increase of 47.81% [1] - The net profit excluding non-recurring items was 8,412.87 million CNY, reflecting a growth of 45.82% [1] - In Q1 2025, revenue was 18,649.04 million CNY, up 27.73% year-on-year, while net profit was 4,057.85 million CNY, increasing by 32.30% [1] - In Q2 2025, revenue reached 20,087.45 million CNY, a 30.95% year-on-year growth, with net profit at 4,322.54 million CNY, marking a significant increase of 66.10% [1] Business Growth Drivers - The rapid growth in domestic business is attributed to supportive national policies, significant license transactions, and accelerated industry mergers and acquisitions [2] - The demand for recombinant proteins and related biological reagents continues to rise, driven by the recovery of the innovative drug market and increased industry investment [2] CGT Field Development - The company is well-positioned in the cell and gene therapy (CGT) sector, providing comprehensive solutions from drug target discovery to commercial production [3] - It has developed a range of recombinant proteins and unique antibodies for CAR-T product development, enhancing the quality and activity assessment of related products [4] ADC Field Development - Antibody-drug conjugates (ADC) are highlighted as a key focus area, combining targeted antibodies with potent cytotoxic agents to improve treatment efficacy while minimizing side effects [6] - The development of ADCs relies on five critical elements: suitable antigen targets, highly specific antibodies, effective toxin molecules, quality linkers, and precise drug-antibody ratios (DAR) [7] - The company offers a variety of high-quality products and services to support ADC drug development, covering the entire research and development chain from antibody preparation to production quality control [7]

8月20日，百普赛斯跌0.28%，成交额1.17亿元，换手率1.65%，总市值94.87亿元。 异动分析 来源：新浪证券-红岸工作室 重组蛋白+细胞免疫治疗+猴痘概念+专精特新+人民币贬值受益 3、2023年7月14日互动易：公司已经关注猴痘病毒传播情况，并启动相关产品的开发工作，目前以已上 线多款重组蛋白、抗体以及试剂盒产品，助力相关预防性疫苗及治疗性药物的开发。 主力没有控盘，筹码分布非常分散，主力成交额3529.65万，占总成交额的3.61%。 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部国家级专 精特新小巨人企业名单。 5、根据2024年年报，公司海外营收占比为66.46%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-559.97万，占比0.05%，行业排名27/54，连续3日被主力资金减仓；所属行 ...

Financial Performance - In 2024, the company achieved a revenue of 645.02 million CNY, a year-on-year increase of 18.65%, with overseas revenue (excluding specific acute respiratory disease-related products) growing over 20% [1] - For Q1 2025, the company reported a revenue of 186.49 million CNY, reflecting a year-on-year growth of 27.73%, and a net profit of 40.58 million CNY, up 32.30% [1] Business Strategy - The company focuses on biomedicine and cell immunotherapy, emphasizing a market-oriented, customer-first, and innovation-driven R&D approach [1] - A comprehensive internal management optimization has been implemented to enhance the marketing network and overall competitiveness [1] Global Operations - The company has established a logistics system covering nearly 80 countries and regions, serving over 10,000 industrial and research clients [3] - A robust internal communication mechanism supports seamless collaboration across global branches [3] Cell and Gene Therapy (CGT) - The company offers comprehensive solutions for CGT, leveraging its extensive protein pipeline and technical expertise [4] - Over 50 high-quality GMP-grade products have been developed, supporting clinical research and commercial production [6] Antibody-Drug Conjugates (ADC) - ADCs are highlighted as a key focus area, combining targeted antibodies with potent chemotherapy agents to enhance treatment efficacy while minimizing side effects [7] - The company provides a range of products and services for ADC development, covering the entire process from antibody preparation to quality control [8] Neuroscience Research - The company is actively involved in neuroscience, providing high-quality recombinant proteins and pre-formed fibrils (PFFs) for research on neurodegenerative diseases [9] - Products developed for Alzheimer's, Parkinson's, and Huntington's diseases support both treatment and diagnostic research [9]